IP Library Granted Patent US 8,877,263
Granted Patent B2
US 8,877,263 · App. 14/254,510 · Granted Nov 4, 2014

Modified pectins, compositions and methods related thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,263
App. No.
14/254,510
Granted
Nov 4, 2014
Kind
B2
Abstract

The present invention provides compositions of modified pectin and methods for preparing and using them.

Claims (21)

1. A method of treating chronic inflammation in a patient in need thereof, comprising parenterally administering to the patient a therapeutically effective amount of an aqueous solution of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the solution is substantially free of modified pectins having molecular weights below 25 kD.

2. The method of claim 1 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 50-200 kD.

3. The method of claim 2 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 70-150 kD.

4. A method of treating chronic inflammation in a patient in need thereof, comprising parenterally administering to the patient a therapeutically effective amount of an aqueous solution of a purified modified pectin or a purified, deesterified, and partially depolymerized modified pectin, wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 70-150 kD.

5. The method of claim 4 , wherein the average molecular weight of the purified modified pectin or purified, deesterified, and partially depolymerized modified pectin is from 80-150 kD.

6. The method of claim 5 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 80-100 kD.

7. The method of claim 4 , wherein the aqueous solution is substantially free of modified pectins having molecular weights below 25 kD.

8. The method of claim 1 , wherein the solution contains at least 0.5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

9. The method of claim 8 , wherein the solution contains at least 5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

10. The method of claim 4 , wherein the solution contains at least 0.5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

11. The method of claim 10 , wherein the solution contains at least 5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

12. The method of claim 1 , wherein the aqueous solution comprises a deesterified and partially depolymerized modified pectin.

13. The method of claim 4 , wherein the aqueous solution comprises a deesterified and partially depolymerized modified pectin.

14. The method of claim 1 , wherein the aqueous solution comprises a modified pectin.

15. The method of claim 4 , wherein the aqueous solution comprises a modified pectin.

16. The method of claim 14 , wherein the modified pectin consists essentially of a homogalacturonan backbone with small amounts of rhamnogalacturonan therein, wherein the backbone has neutral sugar side chains having a low degree of branching dependent from the backbone.

17. The method of claim 16 , wherein the galacturonic acid subunits of the backbone have been substantially deesterified.

18. The method of claim 15 , wherein the modified pectin consists essentially of a homogalacturonan backbone with small amounts of rhamnogalacturonan therein, wherein the backbone has neutral sugar side chains having a low degree of branching dependent from the backbone.

19. The method of claim 18 , wherein the galacturonic acid subunits of the backbone have been substantially deesterified.

20. The method of claim 1 , wherein parenterally administering comprises injection or intravenous infusion.

21. The method of claim 4 , wherein parenterally administering comprises injection or intravenous infusion.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: GLYCOGENESYS, INC.
To: MARLBOROUGH RESEARCH AND DEVELOPMENT, INC
Reel/Frame 033273/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: STAPLES, MARK; ROLKE, JAMES
To: GLYCOGENESYS, INC.
Reel/Frame 033273/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: TANG CAPITAL PARTNERS, LP
To: SOLANA THERAPEUTICS, INC.
Reel/Frame 033273/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: SOLANA THERAPEUTICS, INC.
To: LA JOLLA PHARMACEUTICAL COMPANY
Reel/Frame 033273/0677 →
MERGER Recorded Jul 9, 2014
From: LA JOLLA PHARMACEUTICAL COMPANY
To: LJPC MERGER SUB, INC.
Reel/Frame 033273/0688 →
CHANGE OF NAME Recorded Jul 9, 2014
From: LJPC MERGER SUB, INC.
To: LA JOLLA PHARMACEUTICAL COMPANY
Reel/Frame 033273/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: MARLBOROUGH RESEARCH AND DEVELOPMENT INC.
To: PROSPECT PHARMACEUTICALS, INC.
Reel/Frame 033283/0727 →
CHANGE OF NAME Recorded Jul 9, 2014
From: PROSPECT PHARMACEUTICALS, INC.
To: PROSPECT THERAPEUTICS, INC.
Reel/Frame 033283/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: PROSPECT PHARMACEUTICALS, INC.
To: TANG CAPITAL PARTNERS LP
Reel/Frame 033283/0785 →